Changes in Alzheimer's Disease Blood Biomarkers in Kidney Failure Before and After Kidney Transplant

Overview

Journal Alzheimers Dement (Amst)

Date 2024 Jul 5

PMID 38966621

Authors

Anneka E Blankenship

Lauren Yoksh

Paul J Kueck

Jonathan D Mahnken

Jill K Morris

Aditi Gupta

Affiliations

Soon will be listed here.

Abstract

Introduction: Alzheimer's disease (AD) blood biomarkers show promise for clinical diagnosis but their reliability in chronic kidney disease (CKD) is debated. This study investigates the impact of kidney transplant (KT) on AD biomarkers in CKD.

Methods: We assessed AD biomarkers in 46 CKD patients pre-KT, at 12 weeks and 12 months post-KT, with baseline measures from 13 non-CKD controls. Using linear mixed models, we examined associations with participant groups, estimated glomerular filtration rate (eGFR) and cognition.

Results: CKD patients showed elevated levels of neurofilament light (117 ± 72 vs. 11 ± 5 pg/mL), phosphorylated tau 181 (75 ± 42 vs. 13 ± 8 pg/mL), glial fibrillary acidic protein (193 ± 127 vs. 94 ± 39 pg/mL), amyloid β 42 (17 ± 5 vs. 5 ± 1 pg/mL), and amyloid β 40 (259 ± 96 vs. 72 ± 17 pg/mL) compared to controls. Post-KT, biomarker levels approached normal with improved eGFR, paralleled by enhanced cognitive function.

Discussion: AD blood biomarker elevations in CKD are reversible with improved kidney function through KT.

Highlights: AD biomarker levels are extremely high in severe CKD.AD biomarker levels are higher in patients with kidney failure on dialysis when compared to CKD patients not on dialysis.These elevations in AD biomarker levels in kidney failure are reversable and decrease dramatically after kidney transplantation.The change in biomarker levels after transplantation align with changes in kidney function.The change in biomarker levels after transplantation align with changes in cognitive function.

Citing Articles

Association between serum neurofilament light chain levels and chronic kidney disease: a cross-sectional population-based study from the National Health and Nutrition Examination Survey (2013-2014 cycle).

Lu J, Kadier K, Dilixiati D, Qiao B, Nuer R, Zebibula A Ren Fail. 2024; 46(2):2427178.

PMID: 39581996 PMC: 11590190. DOI: 10.1080/0886022X.2024.2427178.

References

Janelidze S, Barthelemy N, He Y, Bateman R, Hansson O . Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios. JAMA Neurol. 2023; 80(5):516-522. PMC: 10061310. DOI: 10.1001/jamaneurol.2023.0199. View

Mattsson N, Cullen N, Andreasson U, Zetterberg H, Blennow K . Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019; 76(7):791-799. PMC: 6583067. DOI: 10.1001/jamaneurol.2019.0765. View

Shirk S, Mitchell M, Shaughnessy L, Sherman J, Locascio J, Weintraub S . A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. Alzheimers Res Ther. 2011; 3(6):32. PMC: 3308021. DOI: 10.1186/alzrt94. View

Tian D, Cheng Y, Zhuang Z, He C, Pan Q, Tang M . Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer's disease. Mol Psychiatry. 2021; 26(10):6074-6082. DOI: 10.1038/s41380-021-01073-6. View

Beydoun M, Noren Hooten N, Weiss J, Maldonado A, Beydoun H, Katzel L . Plasma neurofilament light as blood marker for poor brain white matter integrity among middle-aged urban adults. Neurobiol Aging. 2022; 121:52-63. PMC: 9733693. DOI: 10.1016/j.neurobiolaging.2022.10.004. View

Stocker H, Beyer L, Trares K, Perna L, Rujescu D, Holleczek B . Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers. JAMA Netw Open. 2023; 6(1):e2252387. PMC: 10408272. DOI: 10.1001/jamanetworkopen.2022.52387. View

Lipnicki D, Crawford J, Kochan N, Trollor J, Draper B, Reppermund S . Risk Factors for Mild Cognitive Impairment, Dementia and Mortality: The Sydney Memory and Ageing Study. J Am Med Dir Assoc. 2017; 18(5):388-395. DOI: 10.1016/j.jamda.2016.10.014. View

Levey A, Coresh J, Greene T, Stevens L, Zhang Y, Hendriksen S . Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145(4):247-54. DOI: 10.7326/0003-4819-145-4-200608150-00004. View

Morris J, Weintraub S, Chui H, Cummings J, DeCarli C, Ferris S . The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006; 20(4):210-6. DOI: 10.1097/01.wad.0000213865.09806.92. View

10.

Huang X, Yuan S, Ling Y, Cheng H, Tan S, Xu A . Evaluating the effect of kidney function on brain volumes and dementia risk in the UK Biobank. Arch Gerontol Geriatr. 2023; 116:105157. DOI: 10.1016/j.archger.2023.105157. View

11.

Xu H, Garcia-Ptacek S, Trevisan M, Evans M, Lindholm B, Eriksdotter M . Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study. Neurology. 2021; 96(24):e2956-e2965. PMC: 8253567. DOI: 10.1212/WNL.0000000000012113. View

12.

Elahi F, Casaletto K, La Joie R, Walters S, Harvey D, Wolf A . Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease. Alzheimers Dement. 2019; 16(4):681-695. PMC: 7138729. DOI: 10.1016/j.jalz.2019.09.004. View

13.

Syrjanen J, Campbell M, Algeciras-Schimnich A, Vemuri P, Graff-Radford J, Machulda M . Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2021; 18(6):1128-1140. PMC: 8957642. DOI: 10.1002/alz.12466. View

14.

Lepping R, Montgomery R, Sharma P, Mahnken J, Vidoni E, Choi I . Normalization of Cerebral Blood Flow, Neurochemicals, and White Matter Integrity after Kidney Transplantation. J Am Soc Nephrol. 2020; 32(1):177-187. PMC: 7894653. DOI: 10.1681/ASN.2020050584. View

15.

Green Z, Kueck P, John C, Burns J, Morris J . Blood Biomarkers Discriminate Cerebral Amyloid Status and Cognitive Diagnosis when Collected with ACD-A Anticoagulant. Curr Alzheimer Res. 2023; 20(8):557-566. PMC: 10792989. DOI: 10.2174/0115672050271523231111192725. View

16.

Kurella Tamura M, Gaussoin S, Pajewski N, Chelune G, Freedman B, Gure T . Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial. J Am Soc Nephrol. 2020; 31(9):2122-2132. PMC: 7461687. DOI: 10.1681/ASN.2020010038. View

17.

Suchy-Dicey A, Laha T, Hoofnagle A, Newitt R, Sirich T, Meyer T . Tubular Secretion in CKD. J Am Soc Nephrol. 2015; 27(7):2148-55. PMC: 4926962. DOI: 10.1681/ASN.2014121193. View

18.

Wang M, Ding D, Zhao Q, Wu W, Xiao Z, Liang X . Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study. Alzheimers Res Ther. 2021; 13(1):21. PMC: 7798296. DOI: 10.1186/s13195-020-00729-9. View

19.

Binette A, Janelidze S, Cullen N, Dage J, Bateman R, Zetterberg H . Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2022; 19(4):1403-1414. PMC: 10499000. DOI: 10.1002/alz.12787. View

20.

Mielke M, Dage J, Frank R, Algeciras-Schimnich A, Knopman D, Lowe V . Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022; 28(7):1398-1405. PMC: 9329262. DOI: 10.1038/s41591-022-01822-2. View